Allergan to acquire ForSight Vision5

Allergan has entered into an agreement to acquire ForSight Vision5, a clinical-stage biotechnology company focused on eye care, for a $95 million upfront payment. The agreement also includes a launch milestone payment related to ForSight’s lead development program, a periocular ring designed for extended drug delivery to reduce IOP in glaucoma patients, according to a press release.